LOS ANGELES, April 21, 2014 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today
announced that the abstract describing the Company's phase II trial
of dendritic cell-based cancer vaccine ICT-107 in newly diagnosed
glioblastoma (GBM) has been accepted for an oral presentation at
the 2014 American Society for Clinical Oncology (ASCO) annual
meeting, to be held in Chicago
May 30-June 3, 2014.
The abstract accepted for oral presentation is titled, "A
randomized, double‑blind, placebo-controlled phase 2 trial of
dendritic cell (DC) vaccination with ICT-107 in newly diagnosed
glioblastoma (GBM) patients." The principal investigator on the
study, Patrick Y. Wen, MD, Director,
Center for Neuro-Oncology, Dana Farber Cancer Institute, and
Professor Neurology, Harvard Medical
School, will present during the session titled, Central
Nervous System Tumors, on Sunday, June
1st at 8:00-11:00 am
CT. Dr. Wen's presentation is scheduled for 10:00-10:12 am CT. The abstract number is
2005.
"We are honored that the ASCO Scientific Program Committee has
selected our work in newly diagnosed GBM for oral presentation,
typically reserved for important clinical and translational
research findings," said Andrew
Gengos, ImmunoCellular Chief Executive Officer. "We are
looking forward to discussing the ICT-107 phase II results with key
opinion leaders in the neuro-oncology community during, and in
conjunction with, our presentation. We anticipate presenting
updated overall survival results for both the whole trial
population and key predefined sub-groups, as well as important
immunological analyses that can provide insights relative to
vaccine potency and response. This larger and richer data set will
be the basis for informing our phase III design and execution
strategies. We look forward to Dr. Wen's presentation, and want to
express our sincere appreciation for the ongoing interest and
support within the neuro-oncology community for ICT-107's continued
development."
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles area-based clinical-stage company
that is developing immune-based therapies for the treatment of
brain and other cancers. ImmunoCellular has concluded a phase II
trial of its lead product candidate, ICT-107, a dendritic
cell-based vaccine targeting multiple tumor-associated antigens for
glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a
dendritic cell vaccine targeting CD133, and ICT-140, a dendritic
cell vaccine targeting ovarian cancer antigens and cancer stem
cells. To learn more about ImmunoCellular, please visit
www.imuc.com.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements
that are subject to a number of risks and uncertainties, including
the risk that ICT-107 can be further successfully developed or
commercialized. Additional risks and uncertainties are described in
IMUC's most recently filed annual report on Form 10-K. Except as
permitted by law, IMUC undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Logo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
Contact:
ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com
SOURCE ImmunoCellular Therapeutics, Ltd.